Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$108.70 USD

108.70
9,520,162

-1.05 (-0.96%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $108.75 +0.05 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (34 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca's (AZN) Q4 Earnings and Sales Miss Estimates

AstraZeneca (AZN) misses estimates for earnings and sales. However, new drugs, mainly cancer medicines, continue to drive product sales higher.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, AGN Post Q4 Results, Another Alzheimer's Study Fails

AbbVie (ABBV) and Allergan (AGN) announce Q4 results.

Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review

Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.

Merck's Keytruda Meets PFS Endpoint in Breast Cancer Study

Merck's (MRK) immuno-oncology drug, Keytruda, significantly improves progression free survival as first-line treatment for metastatic triple-negative breast cancer patients in a pivotal study.

Signs That Your Trading Will Ruin Your Retirement - February 12, 2020

Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.

Mark Vickery headshot

Top Stock Analyst Reports for Merck, Philip Morris & American Tower

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Philip Morris International (PM) and American Tower (AMT).

Powerful Proof Anyone Can Invest for an Early Retirement - February 11, 2020

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA

The FDA accepts Incyte's (INCY) NDA for capmatinib and grants Priority Review.

What's in Store for AstraZeneca (AZN) This Earnings Season?

AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.

Seattle Genetics (SGEN) Q4 Earnings Top, Adcetris Drives Sales

Seattle Genetics (SGEN) rides high on Q4 earnings and revenue beat.

Kinjel Shah headshot

Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

Bristol-Myers' (BMY) Q4 Earnings & Revenues Beat Estimates

Bristol-Myers (BMY) beats both earnings and sales estimates in the fourth quarter, primarily on robust sales of Eliquis and acquisition of Celgene.

Why Merck (MRK) is a Great Dividend Stock Right Now

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Strong Private Sector Payrolls in January

Strong Private Sector Payrolls in January.

Mark Vickery headshot

ADP Posts Blowout +291K New Jobs for January

Monthly private-sector payrolls from Automatic Data Processing (ADP) for January posted their highest level this morning since May 2015, to a whopping 291K new private-sector jobs having been created.

Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off

Merck (MRK) beats estimates for earnings but misses the same for sales in fourth-quarter 2019. The company plans to spin off Women Health drugs/biosimilars into new company. Shares down.

Should You Buy Merck (MRK) Ahead of Earnings?

Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Merck's Recarbrio Gets FDA Priority Review for New Indication

The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.

Will Opdivo & Eliquis Drive Bristol-Myers (BMY) Q4 Earnings?

Investors will focus on the performance of Opdivo, Revlimid and Eliquis along with the regular top and bottom-line numbers when Bristol-Myers (BMY) reports fourth-quarter results.

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

AbbVie's (ABBV) Q4 top-line results are expected to reflect biosimilar competition for Humira in international markets. However, oncology drugs might demonstrate strong growth.

Bristol-Myers' Opdivo-Yervoy NSCLC Application in EU Withdrawn

Bristol-Myers (BMY) has withdrawn its application in the EU for the Opdivo and Yervoy combo for the treatment of advanced NSCLC based on data from the CheckMate-227 study.

Arrowhead (ARWR) to Report Q1 Earnings: What's in the Cards?

We expect Arrowhead (ARWR) to provide pipeline updates when it releases first-quarter fiscal 2020 results.

Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter results.

Will Eylea & Dupixent Drive Regeneron's (REGN) Q4 Earnings?

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports fourth-quarter 2019 results.

The Extreme Risks of Trading Your Own Retirement Assets - February 03, 2020

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.